Over the years there have been multiple debates about whether different types of androgen deprivation therapy (ADT) really do or don’t extend the survival of men with advanced prostate cancer of differing types and whether the degree to which ADT initially suppresses serum testosterone levels affects that survival. … READ MORE …

Several recent studies shed light on the optimal use of androgen deprivation therapy (ADT) used in conjunction with radiation therapy (RT), including new learnings about timing of ADT, RT dose, and their use in various risk categories. … READ MORE …

So the initial results of the AVIAS trial are not going to make a couple of our regular readers too happy — although at least a trial of the type they have been asking for has now been carried out. … READ MORE …

According to a research letter published in the Journal of the American Medical Association, most men in Ontario, Canada, who have androgen deprivation therapy (ADT) for treatment of prostate cancer have not been receiving bisphosphonate or comparable therapy. … READ MORE …

Back in the late 1980s and early 1990s, the projected survival time for a man diagnosed with evident metastatic prostate cancer (then called D2 disease and now known as TxNxM1 disease) was about 18 to 36 months. Has that really changed in the past 25 years? … READ MORE …

A new paper in Clinical Genitourinary Cancer provides some intriguing information about determining the likelihood of good and less good long-term responses to intermittent androgen deprivation therapy (ADT) among men with non-metastatic prostate cancer. Be warned: This is going to be a long post with a lot of data. … READ MORE …